Dyne Therapeutics (NASDAQ:DYN) Trading Up 3.8% – Should You Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price traded up 3.8% during trading on Tuesday . The company traded as high as $12.81 and last traded at $12.78. 653,044 shares were traded during mid-day trading, a decline of 51% from the average session volume of 1,332,165 shares. The stock had previously closed at $12.31.

Wall Street Analyst Weigh In

DYN has been the topic of several analyst reports. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.85.

Dyne Therapeutics Trading Up 1.8 %

The stock has a 50-day simple moving average of $14.33 and a two-hundred day simple moving average of $24.90. The firm has a market capitalization of $1.42 billion, a P/E ratio of -3.51 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the 3rd quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the third quarter worth about $36,000. US Bancorp DE boosted its position in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics in the 4th quarter worth approximately $50,000. Finally, KBC Group NV raised its position in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after buying an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.